VERONA PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.47 USD | +1.05% |
|
-1.59% | -22.18% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 57.12 | 296.4 | 327.9 | 1,764 | 1,342 | 1,006 | - | - |
| Enterprise Value (EV) 2 | 26.48 | 163.3 | 216.7 | 1,573 | 1,166 | 821.9 | 859.4 | 825.7 |
| P/E ratio | -1.84 x | -3.5 x | -7 x | -25.1 x | -221 x | -24.1 x | -81.4 x | 19.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 10.9 x | 4,633 x | - | 65.5 x | 9.73 x | 3.68 x |
| EV / Revenue | - | - | 7.23 x | 4,131 x | - | 53.6 x | 8.32 x | 3.02 x |
| EV / EBITDA | -651,314 x | -3,132,464 x | - | - | - | - | - | - |
| EV / FCF | -781,950 x | - | - | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 13,173 | 57,899 | 66,021 | 81,634 | 85,951 | 80,984 | - | - |
| Reference price 3 | 5.750 | 7.000 | 6.720 | 26.13 | 19.88 | 15.47 | 15.47 | 15.47 |
| Announcement Date | 2/27/20 | 2/25/21 | 3/3/22 | 3/7/23 | 2/29/24 | - | - | - |
1USD in Million2GBP in Million3USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 29.97 | 0.3807 | - | 15.35 | 103.3 | 273.4 |
| EBITDA | -40.65 | -52.14 | - | - | - | - | - | - |
| EBIT 1 | -41.08 | -52.71 | -54.92 | -62.96 | -53.4 | -87.81 | -41.55 | 138.8 |
| Operating Margin | - | - | -183.28% | -16,539.32% | - | -572.1% | -40.21% | 50.79% |
| Earnings before Tax (EBT) 1 | -39.21 | -46.13 | -41.64 | -56.89 | -42.59 | -83.42 | -36.78 | 142.4 |
| Net income 1 | -31.94 | -46.23 | -41.63 | -57.1 | -42.97 | -83.45 | -38.65 | 129.2 |
| Net margin | - | - | -138.92% | -15,000.24% | - | -543.71% | -37.4% | 47.25% |
| EPS 2 | -3.133 | -2.000 | -0.9600 | -1.040 | -0.0900 | -0.6414 | -0.1900 | 0.7800 |
| Free Cash Flow | -33.86 | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 3/3/22 | 3/7/23 | 2/29/24 | - | - | - |
1GBP in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 29.5 | - | - | - | - | 0.3807 | - | - | - | - | - | 0.2241 | 5.774 | 9.35 | 14.71 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 4.836 | -21.33 | -20.04 | -16.93 | -13.08 | -12.51 | -17.58 | -7.845 | -13.45 | -15.09 | -17.41 | -22.07 | -23.88 | -24.45 | -19.82 |
| Operating Margin | 16.39% | - | - | - | - | -3,285.81% | - | - | - | - | - | -9,845.25% | -413.65% | -261.52% | -134.74% |
| Earnings before Tax (EBT) 1 | 8.244 | -17.61 | -19.79 | -14.6 | -13.48 | -8.663 | -13.12 | -6.689 | -12.08 | -11.21 | -16.15 | -20.83 | -22.83 | -23.62 | -17.98 |
| Net income 1 | 8.151 | -17.43 | -19.86 | -14.67 | -13.53 | -8.687 | -13.26 | -6.933 | -12.11 | -11.17 | -16.15 | -20.84 | -22.84 | -23.62 | -17.96 |
| Net margin | 27.63% | - | - | - | - | -2,281.88% | - | - | - | - | - | -9,296.64% | -395.53% | -252.59% | -122.04% |
| EPS 2 | 0.1600 | -0.4000 | -0.4000 | -0.3200 | -0.0300 | -0.1600 | -0.2400 | -0.0800 | -0.1600 | -0.0200 | -0.1314 | -0.1614 | -0.1871 | -0.1657 | -0.0267 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/3/22 | 5/3/22 | 8/9/22 | 11/9/22 | 3/7/23 | 5/9/23 | 8/3/23 | 11/2/23 | 2/29/24 | - | - | - | - | - |
1GBP in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 30.6 | 133 | 111 | 191 | 177 | 184 | 146 | 180 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -33.9 | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.04 | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 3/3/22 | 3/7/23 | 2/29/24 | - | - | - |
1GBP in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.47
USD
Average target price
34.29
USD
Spread / Average Target
+121.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.18% | 1.25B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- VRNA Stock
- Financials Verona Pharma plc
